MA
BHVN

Montag & Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Montag & Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-863
Closed -$126K – 913
2022
Q2 		$126K Hold
863
– – 0.01% 419
2022
Q1 		$102K Buy
863
+59
+7% +$7.36K 0.01% 464
2021
Q4 		$111K Buy
804
+115
+17% +$14.6K 0.01% 459
2021
Q3 		$96K Buy
+689
New +$86K 0.01% 480

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Montag & Associates's BHVN Position: Q3 2022 in Review

Montag & Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 863 shares — an estimated $126K sold.

Montag & Associates first reported a position in BHVN in Q3 2021 and held it in 4 quarters. The position peaked at $126K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Montag & Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Montag & Associates sold 863 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $126K.
  • Montag & Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 4 quarters.
  • Montag & Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $126K in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Montag & Associates's 13F filing for Q3 2022, filed 9 Nov 2022.